Company intelligence / Profile preview

CardioDx

Redwood City, California, United Statesdicardiology.com ↗

Ownership: Private
Employees: ~110
Development stage: Commercial

Overview

CardioDx developed and commercialized the Corus CAD test, a clinically validated blood-based gene expression diagnostic for obstructive coronary artery disease. The test was used in over 175,000 patients and received Medicare coverage before reimbursement was withdrawn, leading to the company's abrupt closure. Clinical studies demonstrated its utility in improving patient risk stratification compared to traditional noninvasive imaging modalities.

Therapeutic areas: Cardiovascular
Modalities: Molecular diagnosticsGenomic diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Corus CAD

Commercial

Indications: Coronary artery disease

Partnerships

Palmetto GBA/Medicare contractors for reimbursement coverage of Corus CAD prior to withdrawal

Beyond the preview

Go deeper on CardioDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioDx.

Explore the full profile